Skip to content
(515) 717-7648
WellForm MD
← Weight Loss Plateau: Why Progress Stalls and What to Do NextReader

Chapter 9 of 9·2 min left in book

Chapter 9

Sources

I would rather you check than take my word for it. Every clinical number in this book traces to one of the publications below or, where the text says so, to the clinically reviewed WellForm WebBook it was carried from; everything else is either standard physiology found in any medical textbook or my own clinical framing, labeled as such where it appears.

Two reading notes. Trial results are averages of large groups — individual responses spread widely around every mean reported here. And a change measured against placebo means more than a change measured against nothing, which is why the placebo arms appear alongside the treatment numbers in Chapter 4.

Trial evidence for Chapter 4

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002.
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216.
  3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564.

Physiology and weight-loss outcomes

  1. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. New England Journal of Medicine. 1995;332(10):621–628.
  2. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. International Journal of Obesity. 2010;34(Suppl 1):S47–S55.
  3. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. Journal of the American Dietetic Association. 2007;107(10):1755–1767.
  4. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America. 2018;102(1):183–197.
  5. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. New England Journal of Medicine. 2017;376(3):254–266.
  6. Olsson KE, Saltin B. Variation in total body water with muscle glycogen changes in man. Acta Physiologica Scandinavica. 1970;80(1):11–18.
  7. Cappuccio FP, Taggart FM, Kandala NB, et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008;31(5):619–626.

A note on nutrition and training figures

The protein range (one to two grams per kilogram of ideal body weight; 80 to 130 grams a day for many adults) and the resistance-training cadence (two to three sessions a week) carry over from the clinically reviewed WellForm WebBook GLP-1 Side Effects and Safety (edition 2026.1), where they were sourced and approved for the same reader population. They are general education ranges for healthy adults — protein targets in particular must be individualized with your clinician if you have kidney disease or other relevant conditions.

This book is educational material, not a substitute for individualized medical advice. Evidence evolves; editions of this book are versioned, and the edition you are reading is shown on its cover page.